

# Jia-Fong Jhang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/801255/jia-fong-jhang-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

515  
citations

14  
h-index

20  
g-index

48  
ext. papers

699  
ext. citations

2.9  
avg, IF

4.44  
L-index

#	Paper	IF	Citations
43	Possible pathophysiology of ketamine-related cystitis and associated treatment strategies. <i>International Journal of Urology</i> , <b>2015</b> , 22, 816-25	2.3	56
42	Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease. <i>International Neurourology Journal</i> , <b>2016</b> , 20, S95-104	2.6	46
41	Elevated serum IgE may be associated with development of ketamine cystitis. <i>Journal of Urology</i> , <b>2014</b> , 192, 1249-56	2.5	36
40	Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis--clinical results and immunohistochemistry analysis. <i>Urology</i> , <b>2013</b> , 82, 1452.e1-6	1.6	31
39	Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. <i>Toxins</i> , <b>2016</b> , 8, 120	4.9	23
38	Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. <i>LUTS: Lower Urinary Tract Symptoms</i> , <b>2019</b> , 11, O42-O47	1.9	23
37	Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection. <i>Toxins</i> , <b>2015</b> , 7, 2232-50	4.9	22
36	Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198816	3.7	21
35	Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. <i>Tzu Chi Medical Journal</i> , <b>2017</b> , 29, 131-137	1.1	19
34	Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. <i>International Journal of Urology</i> , <b>2014</b> , 21 Suppl 1, 49-55	2.3	18
33	Patient characteristics for different therapeutic strategies in the management ketamine cystitis. <i>Neurourology and Urodynamics</i> , <b>2017</b> , 36, 687-691	2.3	17
32	Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 703-709	2.3	17
31	Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151692	3.7	16
30	Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. <i>Journal of the Formosan Medical Association</i> , <b>2016</b> , 115, 807-13	3.2	15
29	Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 2651-2657	2.3	13
28	Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , <b>2018</b> , 200, 590-596	2.5	12
27	Histopathological characteristics of ketamine-associated uropathy and their clinical association. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 1764-1772	2.3	12

26	Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. <i>Scientific Reports</i> , <b>2020</b> , 10, 15218	4.9	11
25	Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. <i>LUTS: Lower Urinary Tract Symptoms</i> , <b>2019</b> , 11, 66-71	1.9	9
24	Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. <i>Toxins</i> , <b>2018</b> , 10,	4.9	8
23	The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. <i>Pain Physician</i> , <b>2016</b> , 19, E581-7	1.8	8
22	Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 1467-1473	2.3	7
21	Long-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow-up and treatment. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 1985-1993	2.3	7
20	Urothelial Functional Protein and Sensory Receptors in Patients With Interstitial Cystitis/Bladder Pain Syndrome With and Without Hunner's Lesion. <i>Urology</i> , <b>2016</b> , 98, 44-49	1.6	7
19	Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification. <i>Journal of Urology</i> , <b>2017</b> , 197, 221-227	2.5	7
18	Upregulation of neurotrophins and transforming growth factor- $\beta$ expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitis. <i>Neurourology and Urodynamics</i> , <b>2019</b> , 38, 2303-2310	2.3	6
17	Characteristics and electrocauterization of Hunner's lesions associated with bladder pain syndrome. <i>Urological Science</i> , <b>2013</b> , 24, 51-55	0.3	6
16	Current pharmacological and surgical treatment of underactive bladder. <i>Tzu Chi Medical Journal</i> , <b>2017</b> , 29, 187-191	1.1	6
15	Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency. <i>Tzu Chi Medical Journal</i> , <b>2019</b> , 31, 135-143	1.1	6
14	Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy. <i>LUTS: Lower Urinary Tract Symptoms</i> , <b>2019</b> , 11, O221-O223	1.9	5
13	Clinical Outcome of Augmentation Enterocystoplasty for Patients with Ketamine-induced Cystitis. <i>Pain Physician</i> , <b>2017</b> , 20, E431-E436	1.8	5
12	Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade B glomerulation might be different from other types of patients. <i>International Journal of Urology</i> , <b>2021</b> , 28, 823-830	2.3	3
11	Bladder dysfunction in 2016: New insights into interstitial cystitis and chronic pelvic pain syndromes. <i>Nature Reviews Urology</i> , <b>2017</b> , 14, 69-70	5.5	2
10	Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Possible Pathomechanisms and Practical Issues. <i>Toxins</i> , <b>2019</b> , 11,	4.9	2
9	Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection.. <i>International Neurourology Journal</i> , <b>2022</b> ,	2.6	2

8	Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics. <i>Scientific Reports</i> , <b>2021</b> , 11, 17258	4.9	1
7	Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome-A Comparative Study of Different Injection Number, Additives and Concentrations.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 853776	5.6	1
6	Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics.. <i>International Urology and Nephrology</i> , <b>2022</b> , 1	2.3	1
5	Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?. <i>Diagnostics</i> , <b>2022</b> , 12, 1093	3.8	1
4	Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , <b>2022</b> , 10, 1149	4.8	1
3	Ultrastructural changes in the underactive bladder. <i>Tzu Chi Medical Journal</i> , <b>2021</b> , 33, 345-349	1.1	0
2	Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma. <i>Biomedicines</i> , <b>2022</b> , 10, 1182	4.8	0
1	Clinical Correlation of Bladder Electron Microscopic Characteristics in Patients with Detrusor Underactivity of Various Etiologies. <i>Biomedicines</i> , <b>2022</b> , 10, 1055	4.8	